Skip Navigation



NDT Advance Access published online on June 25, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm392
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/10/2749    most recent
gfm392v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jelkmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jelkmann, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Recombinant EPO production–points the nephrologist should know

Wolfgang Jelkmann

Institute of Physiology, University of Luebeck, Luebeck, Germany

Correspondence and offprint requests to: Wolfgang Jelkmann, Institute of Physiology, University of Luebeck, Ratzeburger Allee 160, D-23538 Luebeck, Germany, Email: Jelkmann@physio.uni-luebeck.de

Keywords: biopharmaceuticals; erythropoiesis stimulating agents; erythropoietin; recombinant; renal anemia

The first 150 words of the full text of this article appear below.



   Why should the nephrologist be familiar with EPOs and biosimilars?
 
The administration of recombinant human erythropoietin (rhEPO) and its analogues provides enormous benefit in the prevention and reversal of anaemia in chronic kidney disease (CKD), malignancy and AIDS, and it supports autologous blood collection. rhEPO-type substances represent the largest market of a class of biopharmaceuticals, with global estimated sales of ~1010 euro per annum. The key process patents for the first-generation of rhEPOs have expired in the EU and other regions, opening the market for biosimilar follow-on products. In addition, confronted with imminent patent expiration, the manufacturers of the innovative compounds have developed second-generation products with improved pharmacokinetic properties. Thus, the clinician will be faced with a panoply of different erythropoiesis-stimulating biopharmaceuticals, and it will be important for him to be familiar with their molecular biology.



   The complexities of EPO formation in mammalian cells
 
rhEPO is produced with the use of cells transfected with either the human EPO gene or EPO cDNA (the coding sequence of the . . . [Full Text of this Article]



   The nomenclature of EPO type substances
 


   Differences between current epoetins
 


   Novel epoetins and considerations on their potential safety
 


   EPO congeners
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
W. Jelkmann
Efficacy of recombinant erythropoietins: is there unity of international units?
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1366 - 1368.
[Full Text] [PDF]